NCT02864927View on ClinicalTrials.gov

Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea

PHASE4CompletedINTERVENTIONAL
Enrollment

1,311

Participants

Timeline

Start Date

July 21, 2016

Primary Completion Date

June 12, 2019

Study Completion Date

June 12, 2019

Conditions
MeningitisMeningococcal MeningitisMeningococcal Infections
Interventions
BIOLOGICAL

Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

0.5 mL, Intramuscular. 2 doses 3 months apart

BIOLOGICAL

Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

0.5 mL, Intramuscular

Trial Locations (1)

Unknown

Seoul

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02864927 - Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea | Biotech Hunter | Biotech Hunter